Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFST.L Regulatory News (FST)

  • There is currently no data for FST

Distribution agreement: first commercial US orders

15 Oct 2013 07:00

RNS Number : 4835Q
Toumaz Limited
15 October 2013
 



15 October 2013

 

Toumaz Limited

 

New international distribution agreement for SensiumVitals®; first commercial orders received

 

Toumaz Limited (AIM: TMZ, 'Toumaz', or 'the Group'), a pioneer in low-power wireless semiconductor and software technologies, has signed a significant new North American distribution agreement with NantHealth Group, 'NantHealth', for SensiumVitals®, its ultra-low power system for wireless monitoring of patient vital signs. This new agreement is structured to accelerate the commercial exploitation of SensiumVitals® technology which has now begun.

 

Highlights:

 

· North America - iSirona, a NantHealth subsidiary, will be exclusive distributor of SensiumVitals® in the region

o Direct sales relationships with 250 US hospitals

o First commercial order (of six-figure value) for SensiumVitals® patches and hubs

o Hurley Medical Center, Flint, Michigan becomes the first hospital to deploy SensiumVitals® in the Accident & Emergency Department

· Outside North America - distribution rights shared between Toumaz and NantHealth.

 

This new agreement replaces the previous "Toumaz US" joint venture between Toumaz and NantHealth, and reflects the growth in capabilities of the two companies - in particular, NantHealth's 2012 acquisition of iSirona, a leader in patient monitoring device connectivity.

 

iSirona will be the exclusive distributor of SensiumVitals® in North America - providing a clearly defined and motivated channel to the region. Established in 2008, iSirona is a leading provider of solutions which integrate medical devices into hospital electronic medical records systems. To date, iSirona has introduced its products into 250 hospitals, a number which is increasing rapidly.

 

iSirona is ideally positioned to launch SensiumVitals® in North America as Toumaz Healthcare's wireless monitoring system will be a key component within iSirona's portfolio of connectivity solutions.

 

Toumaz has also received its first sizable commercial order for SensiumVitals®. The system will be deployed at Hurley Medical Center in Flint, Michigan; where for the first time, a wireless patient vital signs tracking system will be used in Accident & Emergency - thereby assisting physicians with the management of patients after triage.

 

In territories outside North America, distribution rights are non-exclusive. Toumaz and NantHealth will both market and sell the SensiumVitals® offering.

 

The Group has also announced today that SensiumVitals® has received its CE Mark for Europe - and will be starting the first pilot deployment in a UK hospital with Spire Healthcare in early 2014 (see separate release).

 

Anthony Sethill,CEO of Toumaz Group, said:

 

"Our commercial deployment of SensiumVitals® has begun. The proven sales capability and market knowledge of iSirona is invaluable and the orders they have already placed are a great indication of the potential of our SensiumVitals® system and wireless health technology.

 

"The significance of our wireless patient monitoring system is starting to resonate with healthcare professionals in both general wards and A&E departments across the US and Europe. The novel use of SensiumVitals® in A&E is one of a number of exciting prospects expected to lead to wider adoption of the technology in hospitals.

 

"As a result of these developments, we are now building our own direct sales force for the UK and Europe - and, over the next two years, will be introducing a number of enhancements to the SensiumVitals® system. We are confident that SensiumVitals® will develop into a major line of business - with applications in a diverse range of healthcare environments."

 

Dave Dyell, CEO of iSirona, said:

 

"This revolutionary system, with its ability to provide early warnings of patient deterioration, has the potential to transform vital signs monitoring. SensiumVitals® is the perfect complement to our patient monitoring offering. We are convinced that together we will make significant inroads into improving patient care."

 

Enquiries:

 

Toumaz Limited

+44 (0)20 7391 0630

Anthony Sethill, Chief Executive Officer

Jonathan Apps, Chief Financial Officer

Peel Hunt LLP (Nominated Adviser and Broker)

+44 (0)20 7418 8900

Richard Kauffer/Daniel Harris

Vijay Barathan (Healthcare & Life Sciences)

College Hill

+44 (0)20 7457 2056

Adrian Duffield/Rozi Morris

 

About Toumaz (www.toumaz.com)

 

Toumaz Limited is a pioneer in low-power, wireless semiconductor and software technologies for healthcare and consumer audio. The company has two divisions, Toumaz Healthcare and Frontier Silicon. Toumaz Healthcare develops wireless solutions for patient monitoring. Frontier Silicon provides chip, modules and software for digital radio and connected audio devices.

 

About SensiumVitals®

 

SensiumVitals® is an ultra-low power system for wireless monitoring of patient vital signs, including heart rate, temperature and respiration. Measurements are taken every two minutes, rather than every four to eight hours, as currently standard in general wards. Patient data is then sent wirelessly and securely to clinicians via hospital IT systems.

 

The key benefit of SensiumVitals® is that it provides clinicians with rapid warnings of patient deterioration, which in turn allows for earlier interventions, shorter stays in hospital and lower healthcare costs.

 

For more information, see http://www.toumaz.com/toumaz-healthcare

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCMIBRTMBBBBLJ
Date   Source Headline
20th Feb 201210:16 amRNSHolding(s) in Company
16th Feb 20127:00 amRNSCompletion of placing
13th Feb 20127:00 amRNSTrading update
13th Feb 20127:00 amRNSPlacing raises £11.2m
3rd Jan 20127:00 amRNSSubsidiary established with Imagination Technologi
24th Oct 20117:00 amRNSTelran distribution clearance
21st Sep 20117:00 amRNSHalf year results
9th Aug 20114:52 pmRNSNotice of Results
29th Jul 20117:00 amRNSHalf year trading update
11th Jul 20117:00 amRNSFDA approval for Sensium
11th Jul 20117:00 amRNSJV established with CCE
5th May 20115:24 pmRNSResult of AGM
29th Mar 20117:00 amRNSFull year results
16th Mar 20113:16 pmRNSNotice of Results
16th Mar 20113:05 pmRNSHolding(s) in Company
3rd Mar 20114:34 pmRNSIssue of Equity
2nd Mar 20118:14 amRNS£1.8m Raised
10th Feb 20117:41 amRNSStrategic Investment
1st Feb 20117:00 amRNSYear End Trading Update
1st Feb 20117:00 amRNSTELRAN Launch
30th Nov 20107:00 amRNSXENIF processor in production
15th Sep 20107:00 amRNSInterim Results
24th Aug 20109:33 amRNSIssue of Equity
11th Aug 201011:52 amRNSNotice of Results
27th Jul 20107:00 amRNSLicense agreement
15th Jul 201010:19 amRNSIssue of Equity and Exercise of Options
30th Jun 20107:00 amRNSTrading Update
16th Jun 20108:49 amRNSAnnual Financial Report
26th May 20109:07 amRNSChange of Name
10th May 20102:52 pmRNSResult of AGM
30th Mar 20107:00 amRNSFinal Results
12th Mar 20109:00 amRNSQuanta takes strategic stake
11th Mar 20104:27 pmRNSDirector dealings
10th Mar 201011:26 amRNSNotice of Results
23rd Feb 20107:00 amRNSClinical Trial Update
1st Feb 20102:02 pmRNSExercise of Options - replacement
29th Jan 201012:33 pmRNSExercise of Options
22nd Dec 200911:19 amRNSHolding(s) in Company
21st Dec 20097:00 amRNSHolding(s) in Company
17th Dec 20093:10 pmPRNResult of EGM
14th Dec 20093:34 pmPRNDirector/PDMR Shareholding
1st Dec 20097:00 amPRNProposed Placing and Update
9th Nov 20091:20 pmRNSNational Microelectronics Institute Award
2nd Nov 20097:00 amPRNSensium Digital Plaster European Trial
28th Sep 20097:00 amPRNHalf-yearly Report
22nd Sep 200912:16 pmRNSHolding(s) in Company
11th Sep 20097:00 amRNSCorrection re holding in company
10th Sep 20097:00 amRNSHolding(s) in Company
7th Aug 200912:01 pmRNSHolding(s) in Company
22nd Jul 200911:21 amPRNResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.